glp 1 in obesity The activity of GLP-1 and GIP for Type 2 Diabetes and Weight loss with GLP-1 medicines
Description
Currently, semaglutide is the best characterized GLP-1 RA in the context of overweight/obesity, CVD risk and kidney disease, but the clinical development program for tirzepatide is expected to be completed with CVD information and preliminary kidney disease results in the next 3 years
The primary mechanism of action involves stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways
STEP 1 for semaglutide 2.4 mg
Gold PW, Goodwin FK, Chrousos GP
